Literature DB >> 32305740

Severe COVID-19 infection associated with endothelial activation.

Robert Escher1, Neal Breakey2, Bernhard Lämmle3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32305740      PMCID: PMC7156948          DOI: 10.1016/j.thromres.2020.04.014

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


× No keyword cloud information.
Mounting evidence supports the strong prognostic importance of D-dimers and the impact of coagulopathy in COVID-19 patients [1,2,3]. We would like to emphasize the significance of anticoagulation in severe COVID-19 disease, by adding our observation of highly pathological data on anti-phospholipid-antibodies, von Willebrand Factor (VWF) and Factor VIII. We observed a 72-year-old previously healthy male patient admitted to our hospital 6 days after the onset of respiratory symptoms and fever. Six days after admission, following a rapid deterioration of his clinical condition with development of acute respiratory distress syndrome, acute renal insufficiency and altered mental status, he was transferred to the intensive care unit (ICU). Supportive care with intubation, positive pressure ventilation and renal replacement therapy led to a stabilization of his condition. During the ICU stay, a continual increase of D-dimers was observed, from initially 0.69 mg/L to 2.55 mg/L on day 4, 2.81 mg/L on day 11 to 20.63 mg/L on day 21. At this time, IgG anti-cardiolipin antibodies (ACA) and anti-beta2-glycoprotein I (anti-β2-GPI) were negative, but IgM ACA elevated at 121.9 CU (normal <20 CU) and IgM anti-β2-GPI elevated at 275.3 CU (normal <20 CU). Furthermore, on day 21, we also observed a concurrent massive elevation of VWF, with VWF:antigen 555% (normal 42–136%) and VWF:activity 520% (normal 42–168%), accompanied by an increase of Factor VIII clotting activity of 369% (normal 55–164%). The increased VWF points towards massive endothelial stimulation and damage with release of VWF from Weibel-Palade bodies. Interestingly, endothelial cells express ACE2, the receptor for SARS-CoV-2, thus possibly mediating endothelial activation [4]. The patient received prophylactic anticoagulation with dalteparin 5000 U s.c. daily from admission to hospital. We increased the dose to therapeutic anticoagulation with unfractionated heparin on day 21, without hemorrhagic complication. Since then, the patient is steadily improving, ventilation and hemodialysis could be successfully withdrawn, and he has been transferred from the ICU to a general ward. D-dimers decreased to 6.26 mg/L on day 24 and to 1.94 mg/L on day 29. Considering the high levels of VWF and factor VIII, we strongly suggest administering higher, possibly therapeutic doses of anticoagulation to these patients. The role of antiphospholipid antibodies, VWF and FVIII needs further study.
  4 in total

1.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.

Authors:  Yan Zhang; Meng Xiao; Shulan Zhang; Peng Xia; Wei Cao; Wei Jiang; Huan Chen; Xin Ding; Hua Zhao; Hongmin Zhang; Chunyao Wang; Jing Zhao; Xuefeng Sun; Ran Tian; Wei Wu; Dong Wu; Jie Ma; Yu Chen; Dong Zhang; Jing Xie; Xiaowei Yan; Xiang Zhou; Zhengyin Liu; Jinglan Wang; Bin Du; Yan Qin; Peng Gao; Xuzhen Qin; Yingchun Xu; Wen Zhang; Taisheng Li; Fengchun Zhang; Yongqiang Zhao; Yongzhe Li; Shuyang Zhang
Journal:  N Engl J Med       Date:  2020-04-08       Impact factor: 91.245

2.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-10       Impact factor: 3.944

3.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.

Authors:  I Hamming; W Timens; M L C Bulthuis; A T Lely; G J Navis; H van Goor
Journal:  J Pathol       Date:  2004-06       Impact factor: 7.996

4.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  4 in total
  159 in total

Review 1.  The complement system in COVID-19: friend and foe?

Authors:  Anuja Java; Anthony J Apicelli; M Kathryn Liszewski; Ariella Coler-Reilly; John P Atkinson; Alfred Hj Kim; Hrishikesh S Kulkarni
Journal:  JCI Insight       Date:  2020-08-06

2.  Von Willebrand factor.

Authors:  Pervinder Bhogal; Melanie Jensen; Dan Hart; Levansri Makalanda; George B Collins; Oliver Spooner; Ounali Jaffer
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

3.  Microthrombotic Complications of COVID-19 Are Likely Due to Embolism of Circulating Endothelial Derived Ultralarge Von Willebrand Factor (eULVWF) Decorated-Platelet Strings.

Authors:  N Varatharajah; Suganthi Rajah
Journal:  Fed Pract       Date:  2020-05-15

4.  Endothelial Dysfunction as a Primary Consequence of SARS-CoV-2 Infection.

Authors:  Genevieve Mezoh; Nigel J Crowther
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.

Authors:  Jae C Chang
Journal:  Vasc Health Risk Manag       Date:  2021-06-01

6.  A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy.

Authors:  Julie Goswami; Taleen A MacArthur; Meera Sridharan; Rajiv K Pruthi; Robert D McBane; Thomas E Witzig; Myung S Park
Journal:  Shock       Date:  2021-06-01       Impact factor: 3.533

7.  The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study.

Authors:  Matsuo So; David J Steiger; Mai Takahashi; Natalia N Egorova; Toshiki Kuno
Journal:  J Thromb Thrombolysis       Date:  2021-05-08       Impact factor: 2.300

Review 8.  Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?

Authors:  Vittorio Pavoni; Lara Gianesello; Andrew Horton
Journal:  J Thromb Thrombolysis       Date:  2021-05-10       Impact factor: 2.300

9.  COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.

Authors:  Emma G Bouck; Frederik Denorme; Alisa S Wolberg; Robert A Campbell; Lori A Holle; Elizabeth A Middelton; Antoinette M Blair; Bas de Laat; Joshua D Schiffman; Christian Con Yost; Matthew T Rondina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-11-16       Impact factor: 8.311

Review 10.  Endothelial Dysfunction and SARS-CoV-2 Infection: Association and Therapeutic Strategies.

Authors:  Hai Deng; Ting-Xuan Tang; Deng Chen; Liang-Sheng Tang; Xiang-Ping Yang; Zhao-Hui Tang
Journal:  Pathogens       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.